ElectroCore’s Non-invasive Nerve Stimulator Effective Against Migraine
ElectroCore Inc (NASDAQ: ECOR)
electroCore Says Entered Into Agreements With Melidonia Health, Cyrus Medical Technologies, Express Medical Solutions
electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with Melidonia Health Services (Melidonia), Cyrus
electroCore Highlights Launch Of New Online Shop In UK
electroCore, Inc. (the “Company”), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United Kingdom. The
elecroCore Shares Quiet Following US Patent & Trademark Office Abstract For Co.’s ‘Systems and methods for vagal nerve stimulation’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6040&f=G&l=50&d=PTXT&p=121&S1=20211207&OS=20211207&RS=20211207
ElectroCore Shares Rise; Zacks Small Cap Research Sets $4.75 Valuation
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Reseach_11052021_ECOR_Vandermosten.pdf
electroCore Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $1.49M Miss $1.56M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 40 percent increase over losses of $(0.10) per share from the same